Using HFCWO therapy shows a reduction in healthcare resource utilization.
PATIENT CHARACTERISTICS, HEALTHCARE RESOURCE UTILIZATION AND OUTCOMES AMONG NON-CYSTIC FIBROSIS BRONCHIECTASIS PATIENTS WITH HIGH FREQUENCY CHEST WALL OSCILLATION (HFCWO) THERAPY
Use of SmartVest as part of a treatment algorithm significantly decreased exacerbations requiring hospitalization and antibiotic use among non-CF bronchiectasis patients.
EMPLOYMENT OF AN ALGORITHM OF CARE INCLUDING CHEST PHYSIOTHERAPY RESULTS IN REDUCED HOSPITALIZATIONS AND STABILITY OF LUNG FUNCTION IN BRONCHIECTASIS
Effectiveness was maintained for 2.5 years after the initiation of SmartVest treatment.
INCIDENCE OF BRONCHIECTASIS-RELATED EXACERBATION RATES AFTER HIGH FREQUENCY CHEST WALL OSCILLATION (HFCWO) TREATMENT — A LONGITUDINAL OUTCOME-BASED STUDY
Bronchiectasis patients saved in healthcare expenditures by using SmartVest.
THE SMARTVEST NON-CYSTIC FIBROSIS BRONCHIECTASIS PERCUSSION VEST COST ANALYSIS
Bronchiectasis patients had a 57% reduction in antibiotics, 59% reduction in hospitalizations, and 60% fewer ED visits.
USING HIGH FREQUENCY CHEST WALL OSCILLATION IN A BRONCHIECTASIS PATIENT POPULATION: AN OUTCOMES-BASED CASE REVIEW